Letter to the editor
Siglec-7 is an inhibitory receptor on human mast cells and basophils

https://doi.org/10.1016/j.jaci.2014.03.031Get rights and content

First page preview

First page preview
Click to open first page preview

Cited by (67)

  • Siglec-9 is an inhibitory receptor on human mast cells in vitro

    2023, Journal of Allergy and Clinical Immunology
  • Roles of Siglecs in neurodegenerative diseases

    2023, Molecular Aspects of Medicine
  • Siglecs in allergy and asthma

    2023, Molecular Aspects of Medicine
View all citing articles on Scopus

The authors acknowledge financial support for this study from a “Kamin” grant of the Israel Ministry of Industry and Trade (Grant no. 46223) and The Aimwell Charitable Trust Foundation (UK) to F.L.-S.; European Cooperation in Science and Technology COST Action BM1007 “Mast Cells and Basophils - Targets for Innovative Therapies” facilitated the collaboration between F.L.-S. and B.F.G. in support of this study. F.L.-S. is a member of the Dr Adolph and Klara Brettler Center for Research in Molecular Pharmacology and Therapeutics and the David R. Bloom Center for Pharmacy at The Hebrew University of Jerusalem's School of Pharmacy.

Disclosure of potential conflict of interest: S. Mizrahi has received travel support from the European Cooperation in Science and Technology COST Action BM1007. B. F. Gibbs has received start-up funds from and is employed by the University of Kent, has received payment for lectures from the University of Virgina and ALK Abello, and has received travel support from EU/ESF COST Action BM1007. F. Levi-Schaffer has received research support from the Israeli Ministry of Industry and Trade (Grant No. 46223); is a member of the Committee for Human Experimentation of New Drugs for the Israeli Ministry of Health; and has received travel support from EU/ESF COST Action BM1007. The rest of the authors declare that they have no relevant conflicts of interest.

These authors contributed equally to this work.

View full text